Edwards Lifesciences Corp (NYSE:EW)

CAPS Rating: 4 out of 5

A global provider of products and technologies designed to treat advanced cardiovascular disease. The Company focuses on specific cardiovascular opportunities including heart valve disease, peripheral vascular disease and critical care technologies.

Recs

1
Player Avatar socalsy (92.68) Submitted: 5/6/2008 1:51:41 PM : Underperform Start Price: $27.75 EW Score: -201.13

Its recent runup makes it overvalued. It would have to grow earnings over 21% a year for the next 5 years to justify $55/share.

Featured Broker Partners


Advertisement